نتائج البحث

1

Hypoxia-inducible factor 1 (HIF-1) is a new therapeutic target in JAK2V617F-positive myeloproliferative neoplasms

المؤلفون: Tim H. Brümmendorf, Nicolas Chatain, Bernd Denecke, Caroline Küstermann, Klaus Strathmann, Tiago Maié, Stephanie Sontag, Martin Zenke, Annika Hubrich, Ivan G. Costa, Julian Baumeister, Andreas Schuppert, Steffen Koschmieder, Deniz Gezer, Kamil R. Kranc, Lijuan Han, Kristin Seré

المصدر: Leukemia. 34:1062-1074

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Cancer Research, Induced Pluripotent Stem Cells, Apoptosis, Echinomycin, Biology, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Polycythemia vera, Biomarkers, Tumor, Tumor Cells, Cultured, medicine, Humans, Progenitor cell, Myelofibrosis, Aged, Cell Proliferation, Aged, 80 and over, Antibiotics, Antineoplastic, Myeloproliferative Disorders, Essential thrombocythemia, Cell Cycle, Hematology, Janus Kinase 2, Middle Aged, Hypoxia-Inducible Factor 1, alpha Subunit, Prognosis, medicine.disease, Warburg effect, Gene Expression Regulation, Neoplastic, Haematopoiesis, 030104 developmental biology, medicine.anatomical_structure, Oncology, chemistry, 030220 oncology & carcinogenesis, Mutation, Cancer research, Female, Bone marrow, Follow-Up Studies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e6aed03294806d5f6aee20d52c51eefTest
https://doi.org/10.1038/s41375-019-0629-zTest

2

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

المصدر: Leukemia. 33:2266-2275

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Population, Antibodies, Monoclonal, Humanized, Article, Cohort Studies, Young Adult, 03 medical and health sciences, chemistry.chemical_compound, Antineoplastic Agents, Immunological, 0302 clinical medicine, Refractory, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Immunologic Factors, Progression-free survival, education, Multiple myeloma, Aged, Aged, 80 and over, Isatuximab, education.field_of_study, Membrane Glycoproteins, business.industry, Antibodies, Monoclonal, Daratumumab, Hematology, Middle Aged, medicine.disease, ADP-ribosyl Cyclase 1, Carfilzomib, Progression-Free Survival, Regimen, 030104 developmental biology, chemistry, 030220 oncology & carcinogenesis, Female, Immunotherapy, Multiple Myeloma, business, Proteasome Inhibitors

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::578f20b4b94ab5eea695d3fdb5fd3826Test
https://doi.org/10.1038/s41375-019-0435-7Test

3

JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation

المصدر: Czech, J, Cordua, S, Weinbergerova, B, Baumeister, J, Crepcia, A, Han, L, Maié, T, Costa, I G, Denecke, B, Maurer, A, Schubert, C, Feldberg, K, Gezer, D, Brümmendorf, T H, Müller-Newen, G, Mayer, J, Racil, Z, Kubesova, B, Knudsen, T, Sørensen, A L, Holmström, M, Kjær, L, Skov, V, Larsen, T S, Hasselbalch, H C, Chatain, N & Koschmieder, S 2019, ' JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation ', Leukemia, vol. 33, no. 4, pp. 995-1010 . https://doi.org/10.1038/s41375-018-0295-6Test

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Cancer Research, CD34, Alpha interferon, Apoptosis, Antiviral Agents, Peripheral blood mononuclear cell, Mice, 03 medical and health sciences, 0302 clinical medicine, Downregulation and upregulation, Pegylated interferon, Biomarkers, Tumor, Tumor Cells, Cultured, medicine, Animals, Humans, Aged, Cell Proliferation, Retrospective Studies, Myeloproliferative Disorders, biology, business.industry, Interferon-alpha, Janus Kinase 1, Hematology, Janus Kinase 2, Middle Aged, Prognosis, Haematopoiesis, STAT1 Transcription Factor, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Mutation, biology.protein, Cancer research, Female, Stem cell, Calreticulin, business, Follow-Up Studies, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56f5523d5077aee3a85880cb282335b6Test
https://doi.org/10.1038/s41375-018-0295-6Test

4

NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome

المؤلفون: Alice S. Mims, Jessica Kohlschmidt, Sophia E. Maharry, Jonathan E. Kolitz, Christopher J. Walker, Shelley Orwick, Eunice S. Wang, Bayard L. Powell, James S. Blachly, Ann-Kathrin Eisfeld, Richard Stone, John C. Byrd, Deedra Nicolet, Albert de la Chapelle, Krzysztof Mrózek, Andrew J. Carroll, Clara D. Bloomfield

المصدر: Leukemia

مصطلحات موضوعية: Male, Adult, 0301 basic medicine, Oncology, congenital, hereditary, and neonatal diseases and abnormalities, Cancer Research, medicine.medical_specialty, Myeloid, Adolescent, Nonsense mutation, Article, Frameshift mutation, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, Internal medicine, medicine, Humans, Missense mutation, neoplasms, Aged, Aged, 80 and over, Neurofibromin 1, business.industry, Remission Induction, Myeloid leukemia, Adult Acute Myeloid Leukemia, Hematology, Middle Aged, Prognosis, medicine.disease, nervous system diseases, 3. Good health, Leukemia, Myeloid, Acute, Leukemia, 030104 developmental biology, medicine.anatomical_structure, Targeted Mutation, 030220 oncology & carcinogenesis, Mutation, Female, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01aeac8269a2e35669d6dc17adf5bbd7Test
https://doi.org/10.1038/s41375-018-0147-4Test

5

Minimal residual disease (MRD) monitoring and mutational landscape in AML with RUNX1-RUNX1T1: a study on 134 patients

المؤلفون: Manja Meggendorfer, Niroshan Nadarajah, Annette Fasan, Claudia Haferlach, Sabine Jeromin, Alexander Höllein, Wolfgang Kern, Torsten Haferlach

المصدر: Leukemia. 32:2270-2274

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f9ff1d75db3f062aafd81b148cbf4f4Test
https://doi.org/10.1038/s41375-018-0086-0Test

6

High frequency of RUNX1 mutation in myelodysplastic syndrome patients with whole-arm translocation of der(1;7)(q10;p10)

المؤلفون: Hongzhi Li, Aining Sun, Yunyun Xu, Lijun Wen, Jinlan Pan, Tongtong Zhang, Qinrong Wang, Suning Chen, Depei Wu

المصدر: Leukemia. 31:2257-2260

مصطلحات موضوعية: Adult, Male, Cancer Research, medicine.medical_specialty, Pathology, Adolescent, animal diseases, viruses, Chromosomal translocation, Biology, Gastroenterology, Translocation, Genetic, Fusion gene, Young Adult, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, hemic and lymphatic diseases, Internal medicine, medicine, Humans, Aged, Aged, 80 and over, Hematology, Middle Aged, medicine.disease, Lymphoma, Leukemia, Oncology, RUNX1, chemistry, Chromosomes, Human, Pair 1, Karyotyping, Myelodysplastic Syndromes, 030220 oncology & carcinogenesis, Core Binding Factor Alpha 2 Subunit, Mutation, embryonic structures, Mutation (genetic algorithm), Female, sense organs, 030215 immunology

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e97a7e45ad69a48d9b35b983e6b40407Test
https://doi.org/10.1038/leu.2017.228Test

7

Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients

المؤلفون: Karin Tarte, Thomas E. Witzig, Imane Azzaoui, Thomas M. Habermann, Andrew L. Feldman, Céline Pangault, Noel Milpied, Stephen M. Ansell, Thierry Fest, Marie Parrens, Matthew J. Maurer, James R. Cerhan, Delphine Rossille, Mikael Roussel, Susan L. Slager, Thierry Lamy, Gaëlle Labouré, Brian K. Link

المساهمون: Microenvironment, Cell Differentiation, Immunology and Cancer (MICMAC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Pontchaillou [Rennes], Mayo Clinic [Rochester], CHU Bordeaux [Bordeaux], University of Iowa [Iowa City], This study is supported by the French Health Minister (BMS_LyTrans project, NCT01287923), the National Institute of Cancer (INCa Translational Research 2010), the French Lymphoma Study Association (LYSA), the French National Agency for Research (ANR Carnot/CALYM), the National Cancer Institute (P50 CA97274, R01 CA92153), and the Henry J Predolin Foundation. Concerning the French cohort, we are indebted to the LYSA pathology platform (Hôpital Henri Mondor, Créteil) for immunohistochemical experiments, the Centre de Ressources Biologiques CRB-Santé (BB-0033-00056) of the Rennes hospital for providing high quality samples. This work was partly supported by a French National Cancer Institute post-doctoral fellowship (grant number PDOC-RC-GO/07-003) to the first author (D.R.)., Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Chard-Hutchinson, Xavier

المصدر: Leukemia
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2017, 31 (4), pp.988-991. ⟨10.1038/leu.2016.385⟩
Leukemia, 2017, 31 (4), pp.988-991. ⟨10.1038/leu.2016.385⟩

مصطلحات موضوعية: Adult, Male, [SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematology, Cancer Research, medicine.medical_specialty, Adolescent, Programmed Cell Death 1 Receptor, [SDV.CAN]Life Sciences [q-bio]/Cancer, Article, Young Adult, 03 medical and health sciences, 0302 clinical medicine, [SDV.CAN] Life Sciences [q-bio]/Cancer, Refractory, immune system diseases, hemic and lymphatic diseases, Internal medicine, Biomarkers, Tumor, Tumor Microenvironment, medicine, Humans, ComputingMilieux_MISCELLANEOUS, Aged, Aged, 80 and over, Hematology, business.industry, Peripheral tolerance, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Middle Aged, Prognosis, medicine.disease, 3. Good health, Lymphoma, Leukemia, Oncology, Apoptosis, 030220 oncology & carcinogenesis, Immunology, Cancer research, Female, Rituximab, Lymphoma, Large B-Cell, Diffuse, business, Diffuse large B-cell lymphoma, 030215 immunology, medicine.drug